TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Visual Analogue Scale/Scor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parenting Stress Index - 4 Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pain severity after extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in facial measurement to assess swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body temperature, pulse, respiratory rate, blood pressure, and saturation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Infrared Spectroscopy (NIRS) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of drug efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of cCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant stress level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory rate/minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart rate/minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The duration of the baby's crying
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to initial return of spontaneous circulation (ROSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum Annexin A1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Screen failure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cross-over
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VISA-P Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Blood Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to development of cancer
Endpoint domain: Mortality/survival
Primary endpoint: SALT (Syncope-Asystole Latency Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression of Intermediate AMD (iAMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Conversion to neovascular AMD (NV-AMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dynamic balance assessment: Y balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic strength evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution in Investigator Global Assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution in score of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in the environment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Modified Emory Functional Ambulation Profile (mEFAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in perceived chemical content relative to conventional condition - natural
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in perceived chemical content relative to conventional condition - organic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in perceived chemical aftertaste to conventional condition - natural
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in perceived chemical aftertaste to conventional condition - organic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in total puff volume relative to conventional condition - natural
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in total puff volume relative to conventional condition - organic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile (AUC24ss/AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait pattern assessed with the Hasomed RehaGait analyzer pro
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grading of severity in idiopathic normal pressure hydrocephalus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life assessed with EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Experience of security and continuity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Isometric hand strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric pincer force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Localization error distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of symptomatic UTI
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects experiencing ≥1 symptomatic UTI
Endpoint domain: Adverse events/effects
Primary endpoint: changing complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: changing hospital stay time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Compound cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of adequate prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants receiving Meropenem
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants with solicited injection site events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in dependence as measured by the Fagerstrom Test of Cigarette Dependence (FTCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in abstinence-induced cigarette withdrawal as measured by the Minnesota Tobacco Withdrawal Scale (MNWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain intensity and interference during smoking abstinence as measured by the past 24-hour version of the Brief Pain Inventory (BPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensor implant duration without Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Values of free T4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Values of free T3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Values of Thyroid-stimulating hormone (TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of cold or flu symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Memory as assessed by pattern separation task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Memory as assessed by the Hopkins Verbal Learning Test-Revised Edition (HVLT-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive functioning as assessed by the Trail Making Test (TMT), part B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Executive functioning as assessed by the Digit Span Task (digit span backwards)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of fetal growth restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduction in UUI Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment rate for eligible patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of TRIIM-Meds successfully deprescribed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual size of the primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: subacromial bursa thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: supraspinatus tendon thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acromiohumeral distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiotensin metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ACE concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ACE2 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in Hepatitis B Viral Load with Entecavir Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in Hepatitis B Viral Load with Tenofovir Disoproxil Fumarate Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Value of the angle lambda
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular dominance depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regional brain functional abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: autoantigen-specific circulating antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: antigen-specific CD4+ T-cell dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alzheimer's disease assessment scale - cognitive subscale (ADAS-cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in PrEP Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Treatment Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sprinting times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasmatic dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Changes in word accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of worst daily pain score measured over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of least daily pain score measured over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of average daily pain score measured over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngeal preservation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve from 0 to infinity (AUCinf) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half-life (t½λz) of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of anti-inflammatory therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood levels of AMG 386
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Isometric back extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Everyday Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: One-month All-cause Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of prehospital ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of leucine oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in internalization of the thin ideal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: General anxiety disorder-7 (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Health Questionnaire (PHQ)-8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: patient cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Corneal Staining in 9 point Score at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Experience Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants who Experience Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of injured submucosal arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pain on load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate [bpm]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke volume [ml]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Use or prolongation of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective status of complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disability Count
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dengue Virus-Neutralizing Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Loss-of-control eating Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest Mobility Measurement - Axillary region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest Mobility Measurement - Xiphoid region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest Mobility Measurement - Subcostal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core body temperature response to meal consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta ACF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale (VAS) of the labour pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Readiness to change for weight loss
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: change in clinical insight
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Systematic Assessment for Treatment Emergent Events (SAFTEE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with conversion of a positive virtual crossmatch to negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of XH-S002
Endpoint domain: Adverse events/effects
Primary endpoint: Dentin hypersensitivity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Panic Disorder Severity Scale (PDSS) Mean Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first passage of flatus and/or stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vaccine Hesitancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence in counseling or giving the HPV vaccine
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in appendicular lean mass and ALM index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in High-sensitivity C-reactive Protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical performance, peak oxygen consumption (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revised Nottingham Sensory Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Chedoke Arm and Hand Activity Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With No, Mild, Moderate, or Severe Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events of Clinical Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ctDNA level from baseline to 3-4 week after the start of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of doravirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial 10-Meter Walk Test (meters/second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final 10-Meter Walk Test (meters/second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial 6-Minute Walk Test (meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final 6-Minute Walk Test (meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of HER2-low status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy correlation of subjective perception of airways collapsibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in sputum columnar epithelial cells (CEPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in E-cadherin protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of serum AST/ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of lncRNA and miRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in 6MWD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Womac score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Headache Impact Test-6 (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sperm density count/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Total sperm count per ejaculate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of abnormal sperm forms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Frequency of post-surgical complications of grade ≥ 2
Endpoint domain: Adverse events/effects
Primary endpoint: Salivary Alkaline Phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in voice quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain Fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Health Questionnaire - 8 (PHQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Five Facets of Mindfulness Questionnaire (FFMQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional Regulation Questionnaire (ERQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression-free survival (PFS) rate at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose (MTD) or Recommended Phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sleep Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wakefulness Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes